MindWalk Holdings Corp.
HYFT evidence brief
What we can confirm
- Market Cap:
- $65.0M
What it means
What to watch
Prepared research question
What matters most for HYFT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HYFT
MindWalk Holdings Corp. (HYFT) is a Bio-Native AI company that discovers and develops biologic drug candidates using proprietary platforms, with over 20 discovery-originated programs, ten of which are in active clinical trials through partnerships.
Key risk: Low revenue base
Market Cap
$65.0M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
MindWalk Holdings Corp. (HYFT) is a Bio-Native AI company that discovers and develops biologic drug candidates using proprietary platforms, with over 20 discovery-originated programs, ten of which are in active clinical trials through partnerships.
- Over 20 discovery-originated drug candidates have been identified from MindWalk's antibody discovery work, with ten programs in active clinical trials spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease [news · 2026-05-18].
- First-quarter fiscal 2027 revenue was CAD 3.8 million, up 21% year-over-year from CAD 3.2 million [news · 2026-09-14].
- Secured a binding commitment for a US$30 million senior unsecured revolving credit facility to support biologics programs, commercial expansion, and working capital [news · 2026-09-14].
- Launched B Cell Llama™, a platform for discovering VHH nanobodies for bispecific antibodies, multispecific therapeutics, and CAR-T cell therapies [news · 2026-03-06].
- Discovered and validated monoclonal antibodies and intrabodies targeting misfolded, pathogenic TDP-43, implicated in ALS, frontotemporal dementia, and certain forms of Alzheimer's disease [news · 2026-01-14].
What works
- Multiple wholly owned clinical-stage programs (ten in active trials) funded and advanced by partners, indicating a scalable asset-light model [news · 2026-05-18].
- Revenue growth of 21% year-over-year to CAD 3.8 million in Q1 FY2027, suggesting increasing commercial traction [news · 2026-09-14].
- New platform (B Cell Llama™) targeting the growing bispecific and cell therapy markets, with bispecific antibody sales projected to reach US$50 billion by 2030 [news · 2026-03-06].
- Secured a US$30 million unsecured credit facility, providing additional capital for biologics programs and expansion [news · 2026-09-14].
What to weigh
- Revenue remains modest (CAD 3.8 million in Q1 FY2027) relative to the scale of its pipeline and ambitions, indicating early-stage commercialization [news · 2026-09-14].
- The company relies heavily on partner funding for clinical assets, which may limit control over development timelines and revenue sharing [news · 2026-05-18].
- No disclosed profitability or accumulated deficit figures in the provided chunks, leaving financial sustainability unclear [news · 2026-09-14].
- The US$30 million credit facility is unsecured and subject to drawdown terms, which may carry interest or covenants not detailed in the chunks [news · 2026-09-14].
From the filings
Quoted directly from source documents.
MindWalk has over 20 discovery-originated drug candidates, ten in active clinical trials.
“MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease.”
News · May 18, 2026
First-quarter fiscal 2027 revenue was CAD 3.8 million, up 21% year-over-year.
“MindWalk (NASDAQ:HYFT) reported first-quarter fiscal 2027 revenue of CAD 3.8 million, up 21% from CAD 3.2 million a year earlier”
News · September 14, 2026
MindWalk secured a US$30 million unsecured credit facility.
“MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today announced that it has entered into a binding commitment with Sanabil (Cayman) for a senior unsecured revolving credit facility of up to US$30 million.”
News · September 14, 2026
MindWalk launched B Cell Llama™ for VHH nanobody discovery.
“MindWalk Holdings Corp. (NASDAQ: HYFT), a bio-native AI company, today announced B Cell Llama™, a platform for the discovery of VHH nanobodies: the single-domain antibody fragments increasingly recognized as the ideal molecular building blocks for bispecific antibodies, multispecific therapeutics, and CAR-T cell therapies.”
News · March 6, 2026
Catalyst timeline
- 2026-09-14 · Earnings: MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2027 — MindWalk will report financial results for Q1 FY2027 and host a conference call with a management presentation and Q&A.
Risks & what to watch (4)›
Key risks
- Low revenue base — Revenue of CAD 3.8 million in Q1 FY2027 is modest for a company with multiple clinical programs, indicating early-stage monetization [news · 2026-09-14].
- Partner-dependent pipeline — All ten clinical assets are wholly owned, advanced, and funded by partners, giving MindWalk limited control over development and economics [news · 2026-05-18].
- Unsecured credit facility terms — The US$30 million facility is unsecured and may carry interest or covenants not disclosed, potentially affecting cash flow [news · 2026-09-14].
- No profitability disclosed — No net income or accumulated deficit figures are provided in the chunks, leaving financial health unclear [news · 2026-09-14].
What to watch
- Q1 FY2027 financial results and management commentary on September 14, 2026, which will provide updated revenue, cash position, and pipeline progress [news · 2026-09-08].
- Progress of the ten active clinical programs, particularly any Phase 2 or Phase 3 readouts that could trigger milestone payments or partnership expansions [news · 2026-05-18].
- Adoption and partnership deals around the B Cell Llama™ nanobody platform, which targets the growing bispecific and cell therapy markets [news · 2026-03-06].
- Drawdown and use of the US$30 million credit facility, which will indicate capital deployment for biologics programs and commercial expansion [news · 2026-09-14].
Sources: Catalysts · News · Generated October 14, 2026 · How we verify sources →
Run MindWalk Holdings Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MindWalk Holdings Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
27
Total value held
$1.8M
| Holder | Shares | Value |
|---|---|---|
| susquehanna international group, llp | 534,016 | $603K |
| renaissance technologies llc | 232,480 | $263K |
| xtx topco ltd | 172,547 | $195K |
| citadel advisors llc | 147,907 | $167K |
| jane street group, llc | 126,552 | $143K |
| bank of montreal /can/ | 69,947 | $79K |
| bridgeway capital management, llc | 50,000 | $57K |
| ubs group ag | 42,331 | $48K |
| allianz asset management gmbh | 35,000 | $40K |
| gradient capital advisors, llc | 26,551 | $30K |
Showing top 10 of 27 institutional holders of MindWalk Holdings Corp.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 1.8%
- Days to cover
- 4.2
- Shares short
- 811,763
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
HYFT short interestFrequently asked questions
What is the AI investment thesis for MindWalk Holdings Corp.?
MindWalk Holdings Corp. (HYFT) is a Bio-Native AI company that discovers and develops biologic drug candidates using proprietary platforms, with over 20 discovery-originated programs, ten of which are in active clinical trials through partnerships.
Who is the CEO of MindWalk Holdings Corp.?
Dr. Jennifer Lynne Bath Ph.D. is the chief executive officer of MindWalk Holdings Corp. (HYFT).
Where is MindWalk Holdings Corp. headquartered?
MindWalk Holdings Corp. (HYFT) is headquartered in Austin, TX, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.